cbdMD, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- T. Ronan Kennedy
- Full Time Employees
- 42
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2101 Westinghouse Blvd Charlotte NC United States of America 28273
- IPO Date
- Nov 17, 2017
- CIK
- 0001644903
- Website
- cbdmd.com
- Similar Companies
- Business
- cbdMD, Inc. (NYSE American: YCBD) produces and distributes cannabidiol (CBD) products throughout the United States. The company owns and operates consumer hemp-based CBD brands including cbdMD, Paw CBD, hempMD, cbdMD Botanicals, Herbal Oasis and ATRx Labs; cbdMD brand offerings comprise CBD tinctures, gummies, topicals, capsules, drink mixes, ready-to-drink cans, sleep aids, focus aids and calming aids, while Paw CBD provides veterinarian-formulated pet products such as tinctures, chews and topicals, and ATRx features functional mushroom supplements. Founded in 2014 and headquartered in Charlotte, North Carolina, cbdMD focuses on health and wellness solutions for humans and pets through e-commerce, third-party retailers and distributors. In September 2025, cbdMD closed a $1.7 million Series B convertible preferred stock private placement with institutional investors including C/M Capital Master Fund, LP, generating net proceeds of approximately $1.5 million to bolster its balance sheet, support working capital needs and pursue growth in its consumer brands.
Company News
cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness
cbdMD, Inc. (YCBD) Q3 2026 Earnings Call Transcript
cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026
cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results
cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products
cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access
cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina
cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation
cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
Oasis Launches Hemp-Derived Mixer
cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
cbdMD Appoints Wade Brown Chief Marketing Officer
cbdMD, Inc. (YCBD) Q2 2026 Earnings Call Transcript
cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
cbdMD, Inc. (YCBD) Q1 2026 Earnings Call Transcript
cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026
cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results
Herbal Oasis de cbdMD se expande a Luisiana con Morales Beverage Group después de su fuerte impulso en Texas